Logo Image
Back

Bringing Bispecific Antibodies to Practice: Operationalizing Care in Lymphoma Across Academic and Community Settings

Bringing Bispecific Antibodies to Practice: Operationalizing Care in Lymphoma Across Academic and Community Settings

In this OncLive My Treatment Approach discussion, expert panelists review the practical integration of bispecific antibodies into the management of relapsed or refractory B-cell lymphomas, with a focus on real-world implementation, safety management, and care coordination. The conversation explores how clinicians discuss treatment goals with patients, including expected response rates, durability of benefit, and quality-of-life considerations associated with immunotherapy-based approaches. Panelists outline key operational considerations for administering bispecific antibodies, including infusion-center preparation, staff training, and multidisciplinary coordination among physicians, pharmacists, nurses, and emergency care teams. A substantial portion of the discussion addresses safety management, particularly the recognition and treatment of cytokine release syndrome and neurologic toxicities, as well as strategies for infection prevention and monitoring. The experts also emphasize the importance of communication between academic and community practices to maintain continuity of care as patients transition between treatment settings. Finally, the panel discusses emerging data and ongoing clinical trials evaluating bispecific antibodies in combination regimens and earlier lines of therapy, highlighting their growing role in the lymphoma treatment landscape.

Bringing Bispecific Antibodies to Practice: Operationalizing Care in Lymphoma Across Academic and Community Settings

Episodes

All
All

EP. 5: Outpatient CRS Management and Infection Prevention

ByJuan P. Alderuccio, MD,Ariel Perez, MD,Matthew Warrick, PharmD, BCPS, BCOP,Pamela Dudkiewicz, DNP, APRN, AOCNP

This segment focuses on practical strategies for early recognition and management of CRS in the outpatient setting, along with approaches to prevent infections during bispecific antibody therapy. The panel emphasizes that patient education and clear care pathways are critical for safely managing treatment outside the hospital.

EP. 7: Best Practices and Future Directions for Bispecific Antibody Therapy

ByJuan P. Alderuccio, MD,Ariel Perez, MD,Matthew Warrick, PharmD, BCPS, BCOP,Pamela Dudkiewicz, DNP, APRN, AOCNP

This final segment highlights practical lessons learned from implementing bispecific antibody therapies and explores how the field may evolve in the coming years. Panelists emphasize that optimizing outcomes requires multidisciplinary collaboration, standardized protocols, and continuous education across clinical teams.